NeoGenomics (STU:NG9) Total Stockholders Equity : €821.6 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is NeoGenomics Total Stockholders Equity?

NeoGenomics's Total Stockholders Equity for the quarter that ended in Mar. 2025 was €821.6 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. NeoGenomics's Book Value per Share for the quarter that ended in Mar. 2025 was €6.40. The ratio of a company's debt over equity can be used to measure how leveraged this company is. NeoGenomics's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.68.

NeoGenomics Total Stockholders Equity Historical Data

The historical data trend for NeoGenomics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Total Stockholders Equity Chart

NeoGenomics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

570.71

980.83

942.13

863.39

861.73

NeoGenomics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															849.54	850.86	818.30	861.73	821.65

NeoGenomics (STU:NG9) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

NeoGenomics's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(821.649	-	0)	/	128.356
	=	6.40

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

NeoGenomics's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(188.891	+	370.532)	/	821.649
	=	0.68

NeoGenomics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoGenomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (STU:NG9) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

NEO:USA NEO:Mexico NG9:Germany

Address

9490 NeoGenomics Way, Fort Myers, FL, USA, 33912

Website

https://www.neogenomics.com

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

NeoGenomics Headlines

No Headlines